P/B
1,9
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
$470M
Market Cap • 11/10/2026
2016
(10 years)
Founded
2023
(3 years ago)
IPO
NASDAQ
Listing Exchange
Switzerland
Country
Valuation
P/S
401,1
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
4
EPS
—
Market Cap
Market Cap
470M
EV
221,7M
EV/Revenue
189,2
EV/EBITDA
-2
EV/EBIT
-2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-37,1%
Total Yield
-37,1%
Payout
0%
Retained Earnings
-528,4M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
6082,6%
Capex/Revenue
6,3%
Capex/D&A
8%
Capex/OCF
-0,1%
SBC/OCF
—
% PPE
1,4%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
2,3
Debt/Equity
0%
Current Ratio
10,4
Quick Ratio
10,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!